StockpollyBeta
Get App
Delisting riskPopularity #4,171
TCRX · NASDAQ · Biotechnology

TScan Therapeutics (TCRX)

Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.

$0.3658
vs last close+0.01 (+3.10%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue471111233311
Cost of revenue010000000010
Gross profit461111233301
292732353437384240262932
Research & development232225272629303332202223
657877898688
Selling & marketing0−10000000000
General & administrative667877898688
Other expenses0000010001−10
Operating income−25−21−31−34−33−37−36−39−37−24−29−30
221231221100
Interest income332343322211
Interest expense111111111111
Other non-operating income−3−3−2−3−4−2−3−2−2−2−1−1
Income before tax−23−20−30−32−30−36−34−37−36−23−29−30
Net income from continuing operations−23−20−30−32−30−36−34−37−36−23−29−30
Net income−23−20−30−32−30−36−34−37−36−23−29−30
EPS, basic−$0.24−$0.21−$0.32−$0.28−$0.25−$0.30−$0.26−$0.28−$0.28−$0.18−$0.22−$0.23
EPS, diluted−$0.24−$0.21−$0.32−$0.28−$0.25−$0.30−$0.26−$0.28−$0.28−$0.18−$0.22−$0.23
Weighted average shares, basic959595113119121130130130130130130
Weighted average shares, diluted959595113119121130130130130130130
EBITDA−21−17−28−30−28−34−33−36−34−22−27−29
Depreciation & amortization111111111111
EBIT−22−19−29−31−29−35−33−36−35−22−28−30